Our study provides novel evidence of significantly elevated of GDF15 levels in patients with late-onset MADD, suggesting that GDF15 serve as a valuable biomarker for assessing disease progression and severity. The gene discussed is GDF15; the disease is multiple acyl-CoA dehydrogenase deficiency.